title: Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.
abstract: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents. Immunomodulatory drugs are used frequently in its treatment. Using the nominal group technique (NGT) and Delphi method, we created a multidisciplinary, evidence- and consensus-based treatment guideline for JIA based on a systematic literature analysis and three consensus conferences. Conferences were headed by a professional moderator and were attended by representatives who had been nominated by their scientific societies or organizations. 15 statements regarding drug therapy, symptomatic and surgical management were generated. It is recommended that initially JIA is treated with NSAID followed by local glucocorticoids and/or methotrexate if unresponsive. Complementing literature evidence with long-standing experience of caregivers allows creating guidelines that may potentially improve the quality of care for children and adolescents with JIA.
authors.affiliation: HELIOS Children's Hospital, Krefeld, Germany.
authors.forename: Gregor
authors.initials: G
authors.lastname: Dueckers
authors.forename: Nihal
authors.initials: N
authors.lastname: Guellac
authors.forename: Martin
authors.initials: M
authors.lastname: Arbogast
authors.forename: Guenther
authors.initials: G
authors.lastname: Dannecker
authors.forename: Ivan
authors.initials: I
authors.lastname: Foeldvari
authors.forename: Michael
authors.initials: M
authors.lastname: Frosch
authors.forename: Gerd
authors.initials: G
authors.lastname: Ganser
authors.forename: Arnd
authors.initials: A
authors.lastname: Heiligenhaus
authors.forename: Gerd
authors.initials: G
authors.lastname: Horneff
authors.forename: Arnold
authors.initials: A
authors.lastname: Illhardt
authors.forename: Ina
authors.initials: I
authors.lastname: Kopp
authors.forename: Ruediger
authors.initials: R
authors.lastname: Krauspe
authors.forename: Barbara
authors.initials: B
authors.lastname: Markus
authors.forename: Hartmut
authors.initials: H
authors.lastname: Michels
authors.forename: Matthias
authors.initials: M
authors.lastname: Schneider
authors.forename: Wolfram
authors.initials: W
authors.lastname: Singendonk
authors.forename: Helmut
authors.initials: H
authors.lastname: Sitter
authors.forename: Marianne
authors.initials: M
authors.lastname: Spamer
authors.forename: Norbert
authors.initials: N
authors.lastname: Wagner
authors.forename: Tim
authors.initials: T
authors.lastname: Niehues
mesh_terms: D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003245:Consensus Statements as Topic; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D008727:Methotrexate